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Mesenchymal progenitor/stromal/stem cell (MSC) research
has made substantial progress during the past decades.
Investigators have published a wealth of basic science and
preclinical data documenting the potential utility, eﬃcacy,
and safety of MSCs. The majority of this work has focused
on the bone marrow- or adipose-derived MSCs. Since this
body of evidence has set the stage for clinicians to advance
from the bench to the bedside, Stem Cells International
set out to publish a special issue devoted to the topic of
Phases I–III Clinical Trials Using Adult Stem Cells.T h er e s u l t
is a collection of ten outstanding articles submitted by
investigators representing ten countries across Asia, Europe,
and North America. In all cases, the methods section of
each manuscript included a statement documenting that
the clinical investigations were performed following institu-
tional review board approval and/or that patient informed
consent had been provided prior to the conduct of the
study.
Bieback et al. in Germany (Translating research into
clinical scale manufacturing of mesenchymal stromal cells)
and B. Philippe et al. in France (in “Culture and Use
of Mesenchymal Stromal Cells in Phase I and II Clinical
Trials”) have focused on the process of MSC isolation and
expansion with respect to current Good Manufacturing
Practices(cGMP).These authorshighlightthestateoftheart
as well as the challenges facing the development of clinical
grade cells for therapeutic applications.
From a regulatory perspective, the simplest application
of MSC is to use them in the context of their tissue of origin.
S. Akita et al. in Japan (in “Noncultured Autologous Adipose-
Derived Stem Cell Therapy for Chronic Radiation Injury”)
have exploited adipose-derived stem cells for soft tissue
regeneration. They describe their clinical experience using
autologous adipose-derived stem cells in combination with
growth factors and scaﬀold to treat ten patients suﬀering
fromdermalradiationlesions. Aseriesofthreereviewpapers
from Belgium (“Phase 1–3 Clinical Trials Using Adult Stem
Cells in Osteonecrosis and Nonunion Fractures”b yJ .– P .
Hauzeur and V. Gangji), the USA and China (“Mesenchymal
Progenitor Cells and Their Orthopedic Applications: Forging a
Path towards Clinical Trials”b yD .S .S h e n a qe ta l . ) ,a n dt h e
Netherlands (“Clinical Applications of Human Mesenchymal
Stromal Cells for Bone Tissue Engineering”b yC h a t t e r j e a
et al.) have examined the use of bone marrow-derived MSC
for orthopedic applications. Each work provides a unique
perspectiveonthepublishedclinicaltrialsusingMSCtotreat
cartilage and tendon repair, critical sized defects, metabolic
bone diseases, nonunion fractures, and/or osteonecrosis.
From a public health perspective, MSC applications for
common cardiac and central nervous system disorders could2 Stem Cells International
have substantial health and societal beneﬁts. R. Sanz-Ruiz
et al. in Spain (in “Phases I–III Clinical Trials Using Adult
Stem Cells”) have emphasized the critical importance of
randomized clinical trials to assess the utility of MSCs as
they focus on the clinical evidence supporting MSC-based
treatment of cardiac disease. Furthermore, they review the
guidance documents on future clinical trials provided by a
task force convened by the European Society for Cardiology.
P. A. Walker et al. in the USA (in “Progenitor Cell Therapy
forThe Treatment of CentralNervous SystemInjury: AReview
of the State of Current Clinical Trials) provide a similar
perspective relating to central nervous system disorders.
They evaluate the use of bone marrow-derived MSCs for
ischemic stroke, spinal cord injury, and traumatic brain
injury and conclude that there remains a need for further
evidence to support these clinical applications.
There are potential MSC applications for metabolic
disorders as well. A. C. Piscaglia et al. in Italy (in “Stem
Cell Therapies for Liver Disease: State of the Art and New
Perspectives)h a v er e v i e w e dt h el i m i t e dn u m b e ro fc l i n i c a l
trials using hematopoietic stem cell (HSC), MSC infusion,
or cytokine (G-CSF) therapy to reverse hepatic injury due
to cirrhosis, drug exposure, or other causes of end stage
liver disease. Likewise, A. V. Vanikar et al. from India (in
“Cotransplantation of Adipose Tissue-Derived Insulin Secret-
ing Mesenchymal Stem Cells A Novel Therapy for Insulin-
Dependent Diabetes Mellitus”) describe their experience
combining adipose- and bone marrow-derived MSC to treat
a cohort of 11 diabetic subjects for a period of up to 23
months. They report improved hemoglobin A1C levels as
well as decreased daily requirements for exogenous insulin.
Uniformly, these authors highlight both the promise and
the challenges faced by this emerging ﬁeld of medicine.
Their manuscripts identify the critical need for additional
prospective, randomized controlled clinical trials evaluating
all cell-based therapies,regardless ofthe underlying disorder.
In summary, this special issue provides a snapshot of the
current status of MSC-based clinical trials across the globe.
Hopefully, this publication will provide a benchmark for
future meta-analyses evaluating a far greater body of clinical
evidence regarding the safety and eﬃcacy of MSC therapies.
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